Year All20262025202420232022202120202019 September 4, 2024 atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference August 13, 2024 atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 13, 2024 atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) August 7, 2024 atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference June 26, 2024 atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference June 20, 2024 atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a May 31, 2024 atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference May 23, 2024 atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors May 15, 2024 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates April 24, 2024 atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
September 4, 2024 atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 13, 2024 atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024 atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 7, 2024 atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
June 26, 2024 atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 20, 2024 atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
April 24, 2024 atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
